Lipid Accumulation Product: a Simple and Accurate Index for Predicting Metabolic Syndrome in Patients with Adult Growth Hormone Deficiency

Abstract

Purpose: It has been demonstrated that metabolic risk factors were increased in adult growth hormone deficiency (AGHD) patients. Lipid accumulation product (LAP) is a novel biomarker of central lipid accumulation related to risk of metabolic syndrome (MS), diabetes and cardiovascular disease. The aim of this study was to investigate the ability of LAP to identify MS in AGHD Patients.

Materials and methods: In this cross-sectional study, 75 AGHD patients and 75 controls matched with age and gender were enrolled. The general anthropometries and blood biochemical indexes were measured. Body mass index(BMI), waist-hip ratio (WHR), LAP, HOMA-IR were calculated. Receiver operating characteristic (ROC) analysis was used to find out the cut-off points of LAP to predict MS.

Results: Compared with control group, waist circumference (WC), WHR, Systolic blood pressure (SBP), Diastolic blood pressure (DBP), total cholesterol (TC), triglyceride (TG) and LAP were increased in AGHD group, while high density lipoprotein cholesterol (HDL-c) level was lower in AGHD group (P<0.05). The prevalence of MS was 41.3% in AGHD patients. AGHD patients with MS had significantly higher LAP levels compared to those without MS. LAP was highly correlated with components of MS. ROC analysis showed that LAP was a significant discriminator for MS in AGHD patients, and the optimal cutoff point of LAP to predict MS was 44.96 (96.8% sensitivity, 86.4% specificity).

Conclusions: LAP was associated with MS and had a strong and reliable diagnostic accuracy for MS in AGHD patients.

Key words

adult growth hormone deficiency (AGHD) - lipid accumulation product (LAP) - metabolic syndrome (MS)

• References

• 1 Murray RD, Adams JE, Shalet SM. Adults with partial growth hormone deficiency have an adverse body composition. J Clin Endocrinol Metab 2004; 89: 1586-1591
• 2 Abs R, Feldt-Rasmussen U, Mattsson AF et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-defi cient adults – a KIMS database analysis. Eur J Endocrinol 2006; 155: 79-90
• 3 Rosén T, Wirén L, Wilhelmsen L et al. Decreased psychological well-being in adult patients with growth hormone deficiency. Clinical endocrinology 1994; 40: 111-116
• 4 Lo JC, Feigenbaum SL, Yang J et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1357-1363
• 5 van der Klaauw AA, Biermasz NR, Feskens EJM et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. European Journal of Endocrinology 2007; 156: 455-462
• 6 Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-314
• 7 Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome[J]. Life Sci 2009; 84: 705-712
• 8 Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005; 5: 26
• 9 Kahn HS. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care 2006; 29: 151-153
• 10 Wehr E, Gruber HJ, Giuliani A et al. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. J Clin Endocrinol Metab 2011; 96: E986-E990
• 11 Taverna MJ, Martinez-Larrad MT, Frechtel GD et al. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol 2011; 164: 559-567
• 12 Tellechea ML, Aranguren F, Martínez-Larrad MT et al. Ability of lipid accumulation product to identify metabolic syndrome in healthy men from Buenos Aires. Diabetes Care 2009; 32: e85
• 13 Molitch ME, Clemmons DR, Malozowski S et al. Endocrine Society’s Clinical Guidelines Subcommittee. Evaluation and treatment of adult growth hormone deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1621-1634
• 14 Biller BM, Samuels MH, Zagar A et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002; 87: 2067-2079
• 15 Zimmet P, George K, Alberti MM et al. A New International Diabetes Federation (IDF) Worldwide Definition of the Metabolic Syndrome: the Rationale and the Results. Rev Esp Cardiol 2005; 58: 1371-1376
• 16 Sesmilo G, Biller BM, Llevadot J et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000; 133: 111-122
• 17 McCallum RW, Petrie JR, Dominiczak AF et al. Growth hormone deficiency and vascular risk. Clin Endocrinol (Oxf) 2002; 57: 11-24
• 18 González-Duarte D, Madrazo-Atutxa A, Soto-Moreno A et al. Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency. Pituitary 2012; 15: 589-597
• 19 Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288
• 20 Svensson J, Bengtsson BA, Rosen T et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004; 89: 3306-3312
• 21 Verhelst J, Mattsson AF, Luger A et al. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 2011; 165: 881-889
• 22 Van der Klaauw AA, Biermasz NR, Feskens EJ et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 2007; 156: 455-462
• 23 Attanasio AF, Mo D, Erfurth EM et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH) – deficient patients before and after GH replacement. J Clin Endocrinol Metab 2010; 95: 74-81
• 24 Bhat MA, Laway BA, Shah ZA et al. Insulin resistance, metabolic syndrome and chronic low grade inflammation in Sheehan’s syndrome on standard replacement therapy: a case control study. Pituitary 2015; 18: 312-318
• 25 Wang F, Wu S, Song Y et al. Waist circumference, body mass index and waist to hip ratio for prediction of the metabolic syndrome in Chinese. Nutr Metab Cardiovasc Dis 2009; 19: 542-547
• 26 Zaki ME, El-Bassyouni HT, El-Gammal M et al. Indicators of the metabolic syndrome in obese adolescents. Arch Med Sci 2015; 11: 92-98